Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.40 |
| ▸ | TUBB | P07437 | 4/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7174745 | 0.96 | ATM (0.43) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7181231 | 0.94 | HPGD (0.40) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7180961 | 0.92 | ATM (0.45) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7182050 | 0.92 | ATM (0.40) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7181115 | 0.92 | HPGD (0.40) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7175861 | 0.89 | HPGD (0.41) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7182578 | 0.87 | HPGD (0.41) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7187547 | 0.87 | POLB (0.40) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7185485 | 0.86 | ATM (0.44) | ATMHPGDLMNASMN1; SMN2TUBB4A | |
| SCHEMBL7180928 | 0.84 | LMNA (0.39) | HPGDLMNASMN1; SMN2TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579663-B2 | Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides | CIBA SPECIALTY CHEMICALS CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020107413-A1 | Organometallic monoacylarylphosphines | WOLF JEAN-PIERRE (CH) | 2002-08-08 | — | — | US | disclosed |
| US-6399805-B2 | SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES | CIBA SPECIALTY CHEMICALS CORPORATION | 2002-06-04 | — | — | US | disclosed |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | CIBA SPECIALTY CHEMICALS CORP. | 2001-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107413-A1 | Organometallic monoacylarylphosphines | CBR1, NAF1, DHCR24 | ATM 2823/4885HPGD 3983/4885LMNA 3241/4885 |
| US-20010031898-A1 | Organometallic monoacylarylphosphines | NAF1, DHCR24, CBR1 | ATM 2935/4885HPGD 4041/4885LMNA 3247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.